Why Is Small-Cap Cancer Drug Developer Viracta Therapeutics Stock Trading Lower On Monday?
Why Is Small-Cap Cancer Drug Developer Viracta Therapeutics Stock Trading Lower On Monday?
Monday, Viracta Therapeutics Inc (NASDAQ:VIRX) reported topline results from Stage 1 of the pivotal Phase 2 NAVAL-1 trial from both arms of the relapsed or refractory (R/R) Epstein-Barr virus-positive (EBV+) peripheral T-cell lymphoma (PTCL) cohort.
週一，Viracta Therapeutics Inc（納斯達克股票代碼：VIRX）報告了來自復發或難治性（R/R）愛潑斯坦-巴爾病毒陽性（EBV+）外周T細胞淋巴瘤（PTCL）隊列兩個組的關鍵2期 NAVAL-1 試驗的第一階段的主要結果。
Patients were randomized to either nanatinostat monotherapy (n=10) or nanatinostat in combination with valganciclovir (Nana-val, n=10).
患者被隨機分配使用納那替諾司他單一療法（n=10）或納那替諾司他與纈更昔洛韋聯合使用（Nana-VAL，n=10）。
Nana-val (nanatinostat in combination with valganciclovir) demonstrated greater efficacy than nanatinostat monotherapy and was generally well-tolerated. The median duration of response continues to mature.
Nana-VAL（納那替諾司他與纈更昔洛韋聯合使用）顯示出比納那替諾司他單一療法更高的療效，並且總體耐受性良好。中位反應持續時間繼續成熟。
Efficacy was evaluated as of the February 7, 2024 data cutoff date.
截至2024年2月7日數據截止日期，對療效進行了評估。
- In the Nana-val arm, the overall response rate (ORR) was 50%, and the complete response rate (CRR) was 20% in the intent-to-treat (ITT) population (N=10); the ORR was 71%, and the CRR was 29% in the efficacy-evaluable population (N=7).
- 在Nana-val組中，總緩解率（ORR）爲50％，意向治療（ITT）人群的完全反應率（CRR）爲20％（N=10）；ORR爲71％，療效可評估人群的CRR爲29％（N=7）。
In the nanatinostat monotherapy arm, the ORR and CRR were 10% and 0%, respectively, in the ITT population (N=10), and the ORR was 13% in the efficacy-evaluable population (N=8).
在nanatinostat單一療法組中，ITT人群中的ORR和CRR分別爲10％和0％（N=10），療效可評估人群中的ORR爲13％（N=8）。
- Five nanatinostat monotherapy patients crossed over to receive Nana-val, two of whom remain on Nana-val treatment with stable disease as of the data cutoff.
- 五名nanatinostat單一療法患者跨境接受了Nana-Val治療，截至數據截止，其中兩人仍在接受Nana-Val治療，病情穩定。
Safety was also evaluated as of the February 7, 2024 data cutoff date.
截至2024年2月7日數據截止日期，還對安全性進行了評估。
The most common treatment-related adverse events in both treatment arms were thrombocytopenia, anemia, fatigue, decreased appetite, nausea, diarrhea, and weight loss.
兩個治療組中最常見的治療相關不良事件是血小板減少症、貧血、疲勞、食慾不振、噁心、腹瀉和體重減輕。
These adverse events were primarily mild to moderate in severity and generally manageable or reversible.
這些不良事件的嚴重程度主要爲輕度至中度，通常是可控制或可逆的。
Price Action: VIRX shares are down 15.7% at $0.97 on the last check Monday.
價格走勢：週一的最後一次支票中，VIRX股價下跌15.7％，至0.97美元。
Illustration of Phrama lab worker created with MidJourney.
使用 MidJourney 創作的 Phrama 實驗室工作人員的插圖。
譯文內容由第三人軟體翻譯。